Cargando…
Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor
Tanezumab is a monoclonal antibody against nerve growth factor (NGF). We investigated tanezumab pharmacokinetic (PK)‐NGF relationships and predicted the extent of systemic free NGF suppression with target‐mediated drug disposition (TMDD) modeling using data from three pivotal phase III interventiona...
Autores principales: | Shoji, Satoshi, Suzuki, Akiyuki, Nouri, Parya, Cai, Chun‐Hua, Gaitonde, Puneet, Marshall, Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508499/ https://www.ncbi.nlm.nih.gov/pubmed/37470295 http://dx.doi.org/10.1002/psp4.13015 |
Ejemplares similares
-
Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis
por: Patel, Mona K., et al.
Publicado: (2018) -
Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”
por: Tive, Leslie A., et al.
Publicado: (2018) -
Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model
por: LaBranche, Timothy P, et al.
Publicado: (2017) -
Tanezumab: Finally a Monoclonal Antibody for Pain Relief
por: Nair, Abhijit S
Publicado: (2018) -
From the Cover: Evaluation of the Effects of Tanezumab, a Monoclonal Antibody Against Nerve Growth Factor, on the Sympathetic Nervous System in Adult Cynomolgus Monkeys (Macaca fascicularis): A Stereologic, Histomorphologic, and Cardiofunctional Assessment
por: Belanger, Patrice, et al.
Publicado: (2017)